Log In Get Started

Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,781 total articles

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Apr 20, 2026
Caleb Monroe
Press Releases

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo Biosciences announces publication of peer-reviewed research demonstrating the analgesic potential of its FABP5 inhibitor ART26.12 across multiple pain models, highlighting a differentiated mechanism with a favorable safety profile from Phase 1 studies. The company plans to initiate multiple ascending dose trials later this year to advance cl…

ARTL
RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue
Apr 20, 2026
Leila Farooq
Press Releases

RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue

RedCloud Holdings plc is progressing its RAID AI engine from research to live integration within Turkey's leading distribution network, marking a major step towards commercial deployment. This move follows joint ventures in Turkey and Saudi Arabia, collectively valued up to $80 million, reflecting expansion in high-growth FMCG markets amid global s…

RCT
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
Apr 20, 2026
Nina Shah
Press Releases

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

NewcelX Ltd. announced an updated corporate presentation emphasizing its strategic collaboration with Eledon Pharmaceuticals to develop a combined cell therapy and immune-protection approach targeting Type 1 Diabetes. The company's flagship program, NCEL-101, integrates stem-cell-derived islet replacement with Eledon's immune-modulation antibody te…

NCEL
Nexera: KeepZone AI Enters into White Label Agreement to Develop its AI-Based Voice Communication Decision Support System
Apr 20, 2026
Hana Yamamoto
Press Releases

Nexera: KeepZone AI Enters into White Label Agreement to Develop its AI-Based Voice Communication Decision Support System

Nexera Technologies Ltd announced that its wholly-owned subsidiary, KeepZone AI Inc., has entered a white label agreement to develop and commercialize an advanced AI-powered real-time voice communication decision support system. This platform aims to enhance operational capabilities in managing multiple voice and radio communication channels simult…

NEXR
Swvl Announces FY 2025 Results; Revenue Up 41% to $24.2 million; Net Income $1.3 million; NDR of 128%; GCC Revenue Up 122%
Apr 20, 2026
Maya Rios
Press Releases

Swvl Announces FY 2025 Results; Revenue Up 41% to $24.2 million; Net Income $1.3 million; NDR of 128%; GCC Revenue Up 122%

Swvl Holdings Corp announced fiscal year 2025 financial results showing a 41% increase in revenue to $24.2 million and a net income of $1.3 million, marking a return to profitability after a $10.3 million loss in 2024. Revenue growth was driven by significant expansion in the Gulf Cooperation Council (GCC) region, with GCC revenues up 122%, alongsi…

SWVL
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
Apr 20, 2026
Nina Shah
Press Releases

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics announced that results from its Phase 3 SELVA and Phase 2 TOIVA clinical trials evaluating QTORIN™ 3.9% rapamycin anhydrous gel will be presented at the ISSVA World Congress 2026. These studies demonstrated statistically significant and clinically meaningful improvements in treating microcystic lymphatic malformations and cuta…

PVLA
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
Apr 20, 2026
Maya Rios
Press Releases

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell Therapeutics presented positive Phase 3 clinical data demonstrating preserved quality of life in heavily pretreated metastatic breast cancer patients receiving Bria-IMT combined with immune checkpoint inhibitors, alongside promising Phase 2 biomarker analyses at the 2026 AACR Annual Meeting. These findings support BriaCell's immunotherapy …

BCTX
Dragonfly Energy Secures Multi-Million Dollar Order from Stevens Transport, Marking a Major Commercial Milestone
Apr 20, 2026
Nina Shah
Press Releases

Dragonfly Energy Secures Multi-Million Dollar Order from Stevens Transport, Marking a Major Commercial Milestone

Dragonfly Energy announced a material purchase order valued at over $3 million from Stevens Transport for deployment across nearly 500 trucks throughout 2026. This order encompasses Dragonfly's full heavy-duty trucking product portfolio, including lithium-based solutions aimed at reducing engine idling, improving driver comfort, and lowering total …

DFLI
New Found Gold Announces $205M Finance Package
Apr 20, 2026
Hana Yamamoto
Press Releases

New Found Gold Announces $205M Finance Package

New Found Gold Corp. announced a $205 million financing package consisting of a $100 million bought deal equity offering and a $105 million senior secured credit facility with EdgePoint. The funds will finance the initial capital expenditures for the Queensway Gold Project-Phase I, advancing it toward production, as well as general corporate purpos…

NFGC
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Apr 20, 2026
Nina Shah
Press Releases

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic psychedelic therapeutics, announced positive top-line safety data from its ongoing FDA-approved Phase I/IIa trial of CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The drug met the primary safety and tolerability endpoint, showing a hig…

CMND
Gilat to Report First Quarter 2026 Results on Wednesday, May 13th
Apr 20, 2026
Sofia Navarro
Press Releases

Gilat to Report First Quarter 2026 Results on Wednesday, May 13th

Gilat Satellite Networks Ltd., a leader in satellite networking technology, announced it will release its first quarter 2026 financial results on May 13, 2026. The company will host conference calls and webcasts in English and Hebrew to discuss the results and business achievements. Gilat's portfolio includes advanced satellite communication soluti…

GILT
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Apr 20, 2026
Maya Rios
Press Releases

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its drug candidate PAS-004 for the treatment of Neurofibromatosis Type 1 (NF1). This designation supports the drug's potential to address this serious pediatric condition affecting approximately 115,000 individuals in the U.S. PAS-004 already holds…

KTTA
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
Apr 20, 2026
Avery Klein
Press Releases

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics announced encouraging initial findings from the Phase 0/1 HEAT clinical trial evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical, showing meaningful tumor uptake and a favorable safety profile at the lowest 30 mCi dose. The Data Safety and Monitoring Committee has approved advancing to a higher 130 m…

RADX
U.S. Energy Corp. Closes Expanded Senior Secured Debt Facility, Completing Phase 1 Capital Stack for Big Sky Carbon Hub; Formally Suspends Use of Equity Line of Credit
Apr 20, 2026
Maya Rios
Press Releases

U.S. Energy Corp. Closes Expanded Senior Secured Debt Facility, Completing Phase 1 Capital Stack for Big Sky Carbon Hub; Formally Suspends Use of Equity Line of Credit

U.S. Energy Corp. announced the closing of an expanded $20 million senior secured debt facility, together with proceeds from a recent equity offering, expected to complete the Phase 1 capital stack for its Big Sky Carbon Hub. The funding provides financial visibility for Phase 1 construction with commercial operations targeted for Q1 2027. The comp…

USEG
TransAlta Appoints Mike Politeski as Chief Financial Officer and Grant Arnold as Chief Commercial Officer
Apr 20, 2026
Hana Yamamoto
Press Releases

TransAlta Appoints Mike Politeski as Chief Financial Officer and Grant Arnold as Chief Commercial Officer

TransAlta Corporation announced key leadership changes with Mike Politeski joining as EVP and CFO and Grant Arnold as EVP and Chief Commercial Officer, effective May 2026. These appointments coincide with Joel Hunter ascending to President and CEO, following the retirement of John Kousinioris. The new executives bring extensive experience in financ…

Brady Corporation to Acquire Honeywell’s Productivity Solutions and Services Business, Expanding Portfolio with Data Capture and Workflow Solutions
Apr 20, 2026
Leila Farooq
Press Releases

Brady Corporation to Acquire Honeywell’s Productivity Solutions and Services Business, Expanding Portfolio with Data Capture and Workflow Solutions

Brady Corporation announced the acquisition of Honeywell's Productivity Solutions and Services (PSS) business in an all-cash transaction valued at approximately $1.4 billion. The acquisition expands Brady’s product portfolio into leading-edge mobility, scanning, and software solutions that serve enterprise customers in logistics, manufacturing, war…

BRC
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Apr 20, 2026
Maya Rios
Press Releases

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

Monte Rosa Therapeutics presented preclinical data at the AACR 2026 Annual Meeting showcasing the potential of MRT-55811, a first-in-class cyclin E1 (CCNE1)-directed molecular glue degrader. The compound demonstrated strong tumor regression in CCNE1-amplified models of ovarian, breast, and gastric cancers with superior selectivity and reduced off-t…

GLUE
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
Apr 20, 2026
Leila Farooq
Press Releases

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

NRx Pharmaceuticals welcomes President Trump's Executive Order aimed at accelerating the development and approval of psychedelic medications for treating serious mental illnesses such as depression, PTSD, and suicidality. The company’s drug candidate NRX-100 has received FDA Fast Track designation and anticipates submitting a New Drug Application w…

NRXP
Kustom Entertainment, Inc. Announces Reverse Stock Split
Apr 20, 2026
Ajmal Hussain
Press Releases

Kustom Entertainment, Inc. Announces Reverse Stock Split

Kustom Entertainment, Inc. declared a 1-for-5 reverse stock split of its common stock effective April 22, 2026, to raise its share price above Nasdaq's $1.00 minimum requirement. The reverse split includes a proportional reduction in authorized common shares, aiming to ensure continued listing on Nasdaq. The company specializes in advanced video re…

KUST